No Data
Express News | CASI Pharmaceuticals: Accrual to Phase 1-2 Study of Cid-103 Expected to Commence in Q1 2025
Express News | CASI Pharmaceuticals: Cid-103 Ind Application Supporting Phase 1-2 Study of Cid-103 in Adults With Chronic Immune Thrombocytopenia Remains Open
Express News | CASI Pharmaceuticals: FDA Plans to Provide Formal Written Response Before Statutory Deadline
Express News | CASI Pharmaceuticals Inc: Announces Clinical Hold of Cid-103 for Antibody Mediated Rejection (Amr) of Kidney Transplant
Express News | CASI Pharmaceuticals Inc Files for Mixed Shelf Offering of up to $200 Mln- SEC Filing
CASI Pharmaceuticals Faces Evomela License Termination Dispute